Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-01-14

AUTHORS

Sevil Kamali, Ayse Cefle, Mehmet Sayarlioglu, Ahmet Gul, Murat Inanc, Lale Ocal, Orhan Aral, Meral Konice

ABSTRACT

We aimed to investigate the efficacy and safety profile of high-dose intravenous immunoglobulin (HD-IVIG) therapy in patients with severe systemic lupus erythematosus (SLE), inflammatory muscle disease (IMD), Wegener’s granulomatosis (WG), and/or concurrent infection who failed to respond to standard therapies. We evaluated the records of eight patients with SLE, eight with IMD, and four with WG who were treated with HD-IVIG (2 g/kg per month for 1–12 months) for active disease in 19 patients and concurrent infection in three (mycobacterial in two with SLE and cytomegaloviral in one with WG). Systemic lupus erythematosus disease activity index (SLEDAI) scores before and after HD-IVIG were statistically analysed. Remission was achieved in 14 cases (70%). The SLEDAI scores significantly decreased in patients with SLE (P=0.02). No serious side effect was observed. High-dose IVIG may be used as an adjunctive treatment in connective tissue diseases that do not respond to standard therapies or as alternative treatment for patients with concurrent severe infections or for whom immunosuppressives are contraindicated. More... »

PAGES

211-214

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00296-003-0422-0

DOI

http://dx.doi.org/10.1007/s00296-003-0422-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037549315

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/14722731


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Age Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Connective Tissue Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Granulomatosis with Polyangiitis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoglobulins, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lupus Erythematosus, Systemic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myositis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sex Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "T\u00fdp Fak\u00fcltesi, \u00ddstanbul \u00dcniversitesi, \u00dd\u00e7 Hastal\u00fdklar\u00fd Anabilim Dal\u00fd, Romatoloji Bilim Dal\u00fd, Millet cad. \u00c7apa, 34390, Istanbul, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.9601.e", 
          "name": [
            "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey", 
            "T\u00fdp Fak\u00fcltesi, \u00ddstanbul \u00dcniversitesi, \u00dd\u00e7 Hastal\u00fdklar\u00fd Anabilim Dal\u00fd, Romatoloji Bilim Dal\u00fd, Millet cad. \u00c7apa, 34390, Istanbul, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kamali", 
        "givenName": "Sevil", 
        "id": "sg:person.0745230634.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745230634.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.9601.e", 
          "name": [
            "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cefle", 
        "givenName": "Ayse", 
        "id": "sg:person.01314656523.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314656523.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.9601.e", 
          "name": [
            "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sayarlioglu", 
        "givenName": "Mehmet", 
        "id": "sg:person.01113137353.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113137353.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.9601.e", 
          "name": [
            "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gul", 
        "givenName": "Ahmet", 
        "id": "sg:person.0603062573.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603062573.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.9601.e", 
          "name": [
            "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inanc", 
        "givenName": "Murat", 
        "id": "sg:person.01326466673.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326466673.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.9601.e", 
          "name": [
            "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ocal", 
        "givenName": "Lale", 
        "id": "sg:person.01015563063.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015563063.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.9601.e", 
          "name": [
            "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aral", 
        "givenName": "Orhan", 
        "id": "sg:person.01271111427.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271111427.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.9601.e", 
          "name": [
            "Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Konice", 
        "givenName": "Meral", 
        "id": "sg:person.073363076.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.073363076.82"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00320256", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020971193", 
          "https://doi.org/10.1007/bf00320256"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s100670050079", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037623513", 
          "https://doi.org/10.1007/s100670050079"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-01-14", 
    "datePublishedReg": "2004-01-14", 
    "description": "We aimed to investigate the efficacy and safety profile of high-dose intravenous immunoglobulin (HD-IVIG) therapy in patients with severe systemic lupus erythematosus (SLE), inflammatory muscle disease (IMD), Wegener\u2019s granulomatosis (WG), and/or concurrent infection who failed to respond to standard therapies. We evaluated the records of eight patients with SLE, eight with IMD, and four with WG who were treated with HD-IVIG (2\u00a0g/kg per month for 1\u201312\u00a0months) for active disease in 19 patients and concurrent infection in three (mycobacterial in two with SLE and cytomegaloviral in one with WG). Systemic lupus erythematosus disease activity index (SLEDAI) scores before and after HD-IVIG were statistically analysed. Remission was achieved in 14 cases (70%). The SLEDAI scores significantly decreased in patients with SLE (P=0.02). No serious side effect was observed. High-dose IVIG may be used as an adjunctive treatment in connective tissue diseases that do not respond to standard therapies or as alternative treatment for patients with concurrent severe infections or for whom immunosuppressives are contraindicated.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00296-003-0422-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1093123", 
        "issn": [
          "0172-8172", 
          "1437-160X"
        ], 
        "name": "Rheumatology International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "25"
      }
    ], 
    "keywords": [
      "severe systemic lupus erythematosus", 
      "inflammatory muscle disease", 
      "intravenous immunoglobulin therapy", 
      "HD-IVIG", 
      "connective tissue disease", 
      "Wegener's granulomatosis", 
      "immunoglobulin therapy", 
      "standard therapy", 
      "tissue disease", 
      "concurrent infection", 
      "high-dose intravenous immunoglobulin therapy", 
      "Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score", 
      "disease activity index score", 
      "high-dose IVIG", 
      "different connective tissue diseases", 
      "activity index score", 
      "systemic lupus erythematosus", 
      "serious side effects", 
      "SLEDAI score", 
      "active disease", 
      "adjunctive treatment", 
      "lupus erythematosus", 
      "safety profile", 
      "severe infections", 
      "side effects", 
      "alternative treatment", 
      "patients", 
      "index score", 
      "therapy", 
      "disease", 
      "muscle disease", 
      "infection", 
      "granulomatosis", 
      "treatment", 
      "scores", 
      "IVIG", 
      "remission", 
      "erythematosus", 
      "immunosuppressives", 
      "efficacy", 
      "records", 
      "cases", 
      "effect", 
      "experience", 
      "profile", 
      "lupus erythematosus disease activity index (SLEDAI) scores", 
      "erythematosus disease activity index (SLEDAI) scores", 
      "concurrent severe infections"
    ], 
    "name": "Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases", 
    "pagination": "211-214", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037549315"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00296-003-0422-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "14722731"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00296-003-0422-0", 
      "https://app.dimensions.ai/details/publication/pub.1037549315"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_392.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00296-003-0422-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00296-003-0422-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00296-003-0422-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00296-003-0422-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00296-003-0422-0'


 

This table displays all metadata directly associated to this object as RDF triples.

265 TRIPLES      22 PREDICATES      100 URIs      90 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00296-003-0422-0 schema:about N045709b480644a73ac862aa76a070766
2 N09c613180c654f3bb826707bda5b56e5
3 N114aaa1c3787407a8f26cf33fb827bb5
4 N18d55c56b685490299ef88e69de17e5b
5 N29901188a4c04c05918bcc2c08afaf66
6 N2f9d56a300e949d28eb3c0957b25cc0c
7 N540c91c08fbb4ef29e288c3b17885f7b
8 N61ff3c8d254740889d3f98d791844ce1
9 N6de07d0011e84f29bc4df6fa1f472560
10 N79a8b2902d1d465ca924d2c40172850f
11 N7cd95baec935470fa481e82a37e7840d
12 N82810e2364f04a6f9f9220ca1415583f
13 N87a29de44dc9490582dca484f4371b78
14 N8dcceef26ed04d789770e58ffb91486e
15 N93030df4f3af4e65846ecd61590039ae
16 N9542aea815154a69bc05c96436ce7c83
17 Na4ea9d22d1c74d899cccef4a0af1eb8b
18 Na51dedf48fe44868b2d932ebe48d595c
19 Na99d458f70044ae5817b6aeeeb076e30
20 Nb84a41df97d54bb89b103b1e11ec8bf1
21 Nc7288680f89847e9a52ff574fc23f0dc
22 Ncbe7ca13d926443fa800fd05627b21c1
23 Ndf64351ac664407a8c104c383e119425
24 Nf6b40bad235b4849b43a292158d238ea
25 anzsrc-for:11
26 anzsrc-for:1103
27 schema:author Nb414bb996647475e861d88e13a12f132
28 schema:citation sg:pub.10.1007/bf00320256
29 sg:pub.10.1007/s100670050079
30 schema:datePublished 2004-01-14
31 schema:datePublishedReg 2004-01-14
32 schema:description We aimed to investigate the efficacy and safety profile of high-dose intravenous immunoglobulin (HD-IVIG) therapy in patients with severe systemic lupus erythematosus (SLE), inflammatory muscle disease (IMD), Wegener’s granulomatosis (WG), and/or concurrent infection who failed to respond to standard therapies. We evaluated the records of eight patients with SLE, eight with IMD, and four with WG who were treated with HD-IVIG (2 g/kg per month for 1–12 months) for active disease in 19 patients and concurrent infection in three (mycobacterial in two with SLE and cytomegaloviral in one with WG). Systemic lupus erythematosus disease activity index (SLEDAI) scores before and after HD-IVIG were statistically analysed. Remission was achieved in 14 cases (70%). The SLEDAI scores significantly decreased in patients with SLE (P=0.02). No serious side effect was observed. High-dose IVIG may be used as an adjunctive treatment in connective tissue diseases that do not respond to standard therapies or as alternative treatment for patients with concurrent severe infections or for whom immunosuppressives are contraindicated.
33 schema:genre article
34 schema:inLanguage en
35 schema:isAccessibleForFree false
36 schema:isPartOf N4ef301cc6fd04935b842d4c70d98c580
37 Nfaac439af57742c6b081d0eba8d848ca
38 sg:journal.1093123
39 schema:keywords HD-IVIG
40 IVIG
41 SLEDAI score
42 Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score
43 Wegener's granulomatosis
44 active disease
45 activity index score
46 adjunctive treatment
47 alternative treatment
48 cases
49 concurrent infection
50 concurrent severe infections
51 connective tissue disease
52 different connective tissue diseases
53 disease
54 disease activity index score
55 effect
56 efficacy
57 erythematosus
58 erythematosus disease activity index (SLEDAI) scores
59 experience
60 granulomatosis
61 high-dose IVIG
62 high-dose intravenous immunoglobulin therapy
63 immunoglobulin therapy
64 immunosuppressives
65 index score
66 infection
67 inflammatory muscle disease
68 intravenous immunoglobulin therapy
69 lupus erythematosus
70 lupus erythematosus disease activity index (SLEDAI) scores
71 muscle disease
72 patients
73 profile
74 records
75 remission
76 safety profile
77 scores
78 serious side effects
79 severe infections
80 severe systemic lupus erythematosus
81 side effects
82 standard therapy
83 systemic lupus erythematosus
84 therapy
85 tissue disease
86 treatment
87 schema:name Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases
88 schema:pagination 211-214
89 schema:productId N39c9d2a53a49490b8bc0a916ce85cbdf
90 N9bbc5f134054453bab5e809f024a2a5b
91 Nb63cce4897d647e2994e51c5cf0e369c
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037549315
93 https://doi.org/10.1007/s00296-003-0422-0
94 schema:sdDatePublished 2021-12-01T19:16
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher Nec10fd2acb6e44c080c30edcc4c463ae
97 schema:url https://doi.org/10.1007/s00296-003-0422-0
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N045709b480644a73ac862aa76a070766 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Sex Factors
103 rdf:type schema:DefinedTerm
104 N09c613180c654f3bb826707bda5b56e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Myositis
106 rdf:type schema:DefinedTerm
107 N0ea9fc445737402585a094d414cae8a2 rdf:first sg:person.01113137353.97
108 rdf:rest N50f5894994e742829832784367e14fc5
109 N114aaa1c3787407a8f26cf33fb827bb5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Child
111 rdf:type schema:DefinedTerm
112 N18d55c56b685490299ef88e69de17e5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Lupus Erythematosus, Systemic
114 rdf:type schema:DefinedTerm
115 N29901188a4c04c05918bcc2c08afaf66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Drug Administration Schedule
117 rdf:type schema:DefinedTerm
118 N2f9d56a300e949d28eb3c0957b25cc0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Connective Tissue Diseases
120 rdf:type schema:DefinedTerm
121 N31e7647b1c2e4823848b2bb245e37f62 rdf:first sg:person.01271111427.35
122 rdf:rest Nac65dde527a949c5908d7d144bac53f2
123 N39c9d2a53a49490b8bc0a916ce85cbdf schema:name pubmed_id
124 schema:value 14722731
125 rdf:type schema:PropertyValue
126 N48d8075e72b34eb0b793151d93b3933d rdf:first sg:person.01326466673.25
127 rdf:rest Nf8a6797e9e824c26a3181622543a29cf
128 N4ef301cc6fd04935b842d4c70d98c580 schema:issueNumber 3
129 rdf:type schema:PublicationIssue
130 N50f5894994e742829832784367e14fc5 rdf:first sg:person.0603062573.29
131 rdf:rest N48d8075e72b34eb0b793151d93b3933d
132 N540c91c08fbb4ef29e288c3b17885f7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Dose-Response Relationship, Drug
134 rdf:type schema:DefinedTerm
135 N61ff3c8d254740889d3f98d791844ce1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Age Factors
137 rdf:type schema:DefinedTerm
138 N6de07d0011e84f29bc4df6fa1f472560 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Male
140 rdf:type schema:DefinedTerm
141 N79a8b2902d1d465ca924d2c40172850f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Female
143 rdf:type schema:DefinedTerm
144 N7cd95baec935470fa481e82a37e7840d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Middle Aged
146 rdf:type schema:DefinedTerm
147 N82810e2364f04a6f9f9220ca1415583f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Immunoglobulins, Intravenous
149 rdf:type schema:DefinedTerm
150 N87a29de44dc9490582dca484f4371b78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Treatment Outcome
152 rdf:type schema:DefinedTerm
153 N8dcceef26ed04d789770e58ffb91486e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Humans
155 rdf:type schema:DefinedTerm
156 N93030df4f3af4e65846ecd61590039ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Immunosuppressive Agents
158 rdf:type schema:DefinedTerm
159 N9542aea815154a69bc05c96436ce7c83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Survival Rate
161 rdf:type schema:DefinedTerm
162 N9bbc5f134054453bab5e809f024a2a5b schema:name dimensions_id
163 schema:value pub.1037549315
164 rdf:type schema:PropertyValue
165 N9f4b5e2b01a7403f91ffeed01ae7180e rdf:first sg:person.01314656523.31
166 rdf:rest N0ea9fc445737402585a094d414cae8a2
167 Na4ea9d22d1c74d899cccef4a0af1eb8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Granulomatosis with Polyangiitis
169 rdf:type schema:DefinedTerm
170 Na51dedf48fe44868b2d932ebe48d595c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Aged
172 rdf:type schema:DefinedTerm
173 Na99d458f70044ae5817b6aeeeb076e30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Follow-Up Studies
175 rdf:type schema:DefinedTerm
176 Nac65dde527a949c5908d7d144bac53f2 rdf:first sg:person.073363076.82
177 rdf:rest rdf:nil
178 Nb414bb996647475e861d88e13a12f132 rdf:first sg:person.0745230634.05
179 rdf:rest N9f4b5e2b01a7403f91ffeed01ae7180e
180 Nb63cce4897d647e2994e51c5cf0e369c schema:name doi
181 schema:value 10.1007/s00296-003-0422-0
182 rdf:type schema:PropertyValue
183 Nb84a41df97d54bb89b103b1e11ec8bf1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Retrospective Studies
185 rdf:type schema:DefinedTerm
186 Nc7288680f89847e9a52ff574fc23f0dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Adult
188 rdf:type schema:DefinedTerm
189 Ncbe7ca13d926443fa800fd05627b21c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Risk Assessment
191 rdf:type schema:DefinedTerm
192 Ndf64351ac664407a8c104c383e119425 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Adolescent
194 rdf:type schema:DefinedTerm
195 Nec10fd2acb6e44c080c30edcc4c463ae schema:name Springer Nature - SN SciGraph project
196 rdf:type schema:Organization
197 Nf6b40bad235b4849b43a292158d238ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Cohort Studies
199 rdf:type schema:DefinedTerm
200 Nf8a6797e9e824c26a3181622543a29cf rdf:first sg:person.01015563063.46
201 rdf:rest N31e7647b1c2e4823848b2bb245e37f62
202 Nfaac439af57742c6b081d0eba8d848ca schema:volumeNumber 25
203 rdf:type schema:PublicationVolume
204 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
205 schema:name Medical and Health Sciences
206 rdf:type schema:DefinedTerm
207 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
208 schema:name Clinical Sciences
209 rdf:type schema:DefinedTerm
210 sg:journal.1093123 schema:issn 0172-8172
211 1437-160X
212 schema:name Rheumatology International
213 schema:publisher Springer Nature
214 rdf:type schema:Periodical
215 sg:person.01015563063.46 schema:affiliation grid-institutes:grid.9601.e
216 schema:familyName Ocal
217 schema:givenName Lale
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015563063.46
219 rdf:type schema:Person
220 sg:person.01113137353.97 schema:affiliation grid-institutes:grid.9601.e
221 schema:familyName Sayarlioglu
222 schema:givenName Mehmet
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113137353.97
224 rdf:type schema:Person
225 sg:person.01271111427.35 schema:affiliation grid-institutes:grid.9601.e
226 schema:familyName Aral
227 schema:givenName Orhan
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271111427.35
229 rdf:type schema:Person
230 sg:person.01314656523.31 schema:affiliation grid-institutes:grid.9601.e
231 schema:familyName Cefle
232 schema:givenName Ayse
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314656523.31
234 rdf:type schema:Person
235 sg:person.01326466673.25 schema:affiliation grid-institutes:grid.9601.e
236 schema:familyName Inanc
237 schema:givenName Murat
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326466673.25
239 rdf:type schema:Person
240 sg:person.0603062573.29 schema:affiliation grid-institutes:grid.9601.e
241 schema:familyName Gul
242 schema:givenName Ahmet
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603062573.29
244 rdf:type schema:Person
245 sg:person.073363076.82 schema:affiliation grid-institutes:grid.9601.e
246 schema:familyName Konice
247 schema:givenName Meral
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.073363076.82
249 rdf:type schema:Person
250 sg:person.0745230634.05 schema:affiliation grid-institutes:grid.9601.e
251 schema:familyName Kamali
252 schema:givenName Sevil
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745230634.05
254 rdf:type schema:Person
255 sg:pub.10.1007/bf00320256 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020971193
256 https://doi.org/10.1007/bf00320256
257 rdf:type schema:CreativeWork
258 sg:pub.10.1007/s100670050079 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037623513
259 https://doi.org/10.1007/s100670050079
260 rdf:type schema:CreativeWork
261 grid-institutes:grid.9601.e schema:alternateName Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey
262 Týp Fakültesi, Ýstanbul Üniversitesi, Ýç Hastalýklarý Anabilim Dalý, Romatoloji Bilim Dalý, Millet cad. Çapa, 34390, Istanbul, Turkey
263 schema:name Department of Rheumatology, Division of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey
264 Týp Fakültesi, Ýstanbul Üniversitesi, Ýç Hastalýklarý Anabilim Dalý, Romatoloji Bilim Dalý, Millet cad. Çapa, 34390, Istanbul, Turkey
265 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...